Are cancer therapies too targeted?; Teleflex snags FDA clearance for bone delivery tech; Ironwood enters PhII;

> Could cancer therapies be too targeted? Researchers at the Wellcome Trust Sanger Institute have found that narrowly targeted genetic therapies could lead treatments to fail. More

> Teleflex won FDA clearance for its vascular technology designed to deliver drugs to the inner bone. Story

> Ironwood Pharmaceuticals ($IRWD) began a Phase IIa clinical trial of its gastroesophageal reflux disease treatment using Depomed's ($DEPO) Acuform delivery technology. Release

> Researchers at the National Autonomous University of Mexico have developed a nanoparticle that targets cervical cancer cells with minimal side effects. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.